Cerebrovascular Accident: Clinical Trials

30 trials for Cerebrovascular Accident, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 5 terminated, 3 unknown, 1 withdrawn. 30 Phase 2, 6 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 230Completed 21, Terminated 5, Unknown 3, Withdrawn 1
Phase 16Completed 4, Terminated 1, Unknown 1
Phase 32Terminated 2

Follow Cerebrovascular Accident: new trials by email Literature Review of Cerebrovascular Accident trials Research Report on Cerebrovascular Accident

Trials (filtered) newest first · largest first

All 30 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident
Phase 2 / Phase 3TerminatedSolstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC322021-11-022026-05-27
Fluoxetine Opens Window to Improve Motor Recovery After Stroke
Fluoxetine Hydrochloride, Placebo, Exercise Program - Stroke, Cerebrovascular Accident
Phase 2CompletedUniversity Health Network, Toronto522019-01-012022-11-04
Effects of Trunk Exercise on Trunk Control and Balance in Persons With Stroke
trunk exercise on unstable exercise, Upper limb range of motion exercise - Cerebrovascular Accident, Balance Impairment
Phase 1 / Phase 2CompletedNational Cheng Kung University352018-08-092020-06-16
Comparing Constraint-Induced Therapy and Occupation-Based Intervention for Optimal Stroke Recovery
Occupation-based practice (OBP), Modified-constraint induced therapy (m-CIT) - Stroke, Cerebrovascular Accident
Phase 2CompletedLumy Sawaki162013-06-012017-04-20
Proof of Concept (POC) in Patients With Ischaemic Stroke
GSK249320 100/mg, Placebo - Cerebrovascular Accident
Phase 2TerminatedGlaxoSmithKline1342013-05-182017-11-17
Dietary Nitrate Supplements and Ischemic Stroke Recovery
Beet it Beetroot juice, Beet It Placebo Beetroot juice - Stroke, Ischemic Stroke
Phase 2CompletedWake Forest University Health Sciences182012-06-012018-04-10
AMES Treatment of the Impaired Leg in Chronic Stroke Patients
AMES- Leg treatment - Stroke, Cerebrovascular Accident
Phase 1 / Phase 2UnknownAMES Technology222011-01-012016-12-08
Source of Hand Weakness After Stroke
lidocaine, muscle stimulator - Stroke, Cerebrovascular Accident
Phase 2WithdrawnUS Department of Veterans Affairs2009-02-012014-05-05
Home-based Telehealth Stroke Care: A Randomized Trial for Veterans
TR intervention, In-home messaging device., Usual care - Cerebrovascular Accident
Phase 2CompletedUS Department of Veterans Affairs482008-11-012014-11-24
Clinic-Based AMES Treatment of Stroke
Assisted movement and enhanced sensation - Stroke, Cerebrovascular Accident
Phase 1 / Phase 2TerminatedOregon Health and Science University32008-04-012017-01-23
Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke
Armodafinil, Placebo - Stroke, Cerebrovascular Accident
Phase 2CompletedBurke Rehabilitation Hospital192008-01-012019-11-04
Treating Intention In Aphasia: Neuroplastic Substrates
Word-finding with intention component, Word-finding with no intention component - Aphasia, Cerebrovascular Accident
Phase 1 / Phase 2CompletedUniversity of Florida142007-03-012012-05-03
Driving Neuroplasticity With Nerve Stimulation and Modified CIT
peripheral nerve stimulation - Stroke, Cerebrovascular Accident
Phase 1 / Phase 2CompletedUniversity of Kentucky212006-11-012023-09-13
Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke
high intensity functional exercise - Cerebrovascular Accident, Musculoskeletal Equilibrium
Phase 2CompletedUmeå University342006-09-012008-10-29
Post Stroke Hand Functions: Bilateral Movements and Electrical Stimulation Treatments
Bilateral movements and neuromuscular electrical stimulation, Bilateral movements and sham electrical stimulation - Cerebrovascular Accident, Hemiplegia
Phase 2CompletedUniversity of Florida302006-08-012012-06-15
Early Aerobic Training Program After Ischemic Stroke
Supervised aerobic training - Stroke, Cerebrovascular Accident
Phase 2CompletedSheba Medical Center2005-10-012009-10-27
Sit-to-Stand Training for Survivors of Stroke in a Long-Term Care Setting
Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand - Cerebrovascular Accident
Phase 2UnknownHamilton Health Sciences Corporation1202005-01-012005-09-20
Strength Training Effectiveness Post-Stroke (STEPS)
exercise therapy, walking rehabilitation - Cerebrovascular Accident
Phase 2CompletedUniversity of Southern California802004-05-012017-04-06
Trial of Ropinirole in Motor Recovery After Stroke
Ropinirole (+ physical therapy), (vs.) Placebo + physical therapy - Cerebrovascular Accident, Hemiparesis
Phase 2CompletedUniversity of California, Irvine522003-10-012016-11-01
A Study to Evaluate the Effects of ONO-2506 Intravenous Infusion in Patients With Acute Ischemic Stroke
ONO-2506 - Cerebrovascular Accident
Phase 2 / Phase 3TerminatedOno Pharma USA Inc13202002-11-012012-10-11

Showing 20 of 30. Sign in to see all of them.

Narrower conditions

Stroke (30)  ·  Ischemic Stroke (4)  ·  Paresis (4)  ·  Hemiplegia (2)  ·  Motor Activity (2)  ·  Aphasia (1)  ·  Brain Diseases (1)  ·  Brain Infarction (1)  ·  Brain Injuries, Traumatic (1)  ·  Brain Ischemia (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Camurati-Engelmann Syndrome (1)  ·  Central Nervous System Diseases (1)  ·  Cerebral Infarction (1)  ·  Cerebral Palsy (1)

Broader conditions

Cardiovascular Diseases (30)  ·  Brain Diseases (29)  ·  Central Nervous System Diseases (29)  ·  Cerebrovascular Disorders (29)  ·  Nervous System Diseases (29)  ·  Vascular Diseases (29)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Neurologic Manifestations (10)  ·  Signs and Symptoms (10)  ·  Behavior (3)  ·  Immune System Diseases (2)  ·  Musculoskeletal Diseases (2)  ·  Neurobehavioral Manifestations (2)  ·  Paralysis (2)  ·  Autoimmune Diseases (1)

Interventions

Abciximab (2)  ·  Resistance Training (2)  ·  Clinical Trials, Phase II as Topic (1)  ·  Clinical Trials, Phase III as Topic (1)  ·  Constraint Induced Movement Therapy (1)  ·  Exercise Therapy (1)  ·  Fluoxetine (1)  ·  Lidocaine (1)  ·  Modafinil (1)  ·  ONO2506 (1)  ·  Physical Therapy Modalities (1)  ·  Sugars (1)  ·  YM 872 (1)  ·  reteplase (1)  ·  rimabotulinumtoxinB (1)

Sponsors

US Department of Veterans Affairs (5)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (4)  ·  University of Florida (2)  ·  AMES Technology (1)  ·  Astellas Pharma Inc (1)  ·  Burke Rehabilitation Hospital (1)  ·  GlaxoSmithKline (1)  ·  Global Biotech (1)  ·  Hadassah Medical Organization (1)  ·  Hamilton Health Sciences Corporation (1)  ·  Lumy Sawaki (1)  ·  National Cheng Kung University (1)  ·  Ono Pharma USA Inc (1)  ·  Oregon Health and Science University (1)  ·  Sheba Medical Center (1)

Countries

United States (21)  ·  Canada (5)  ·  Germany (3)  ·  Israel (2)  ·  Taiwan (2)  ·  Austria (1)  ·  Belgium (1)  ·  Hungary (1)  ·  Poland (1)  ·  South Africa (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Danielle Kerkovitch, Ph.D. (2)  ·  David Wolff, Ph.D. Special Assistant to the Director (2)  ·  Barry Oken, MD (1)  ·  Bradley MacIntosh, PhD (1)  ·  Bruce Crosson, PhD (1)  ·  Bryan Due, Ph.D. (1)  ·  Cheryl Bushnell, MD (1)  ·  Courtney Pollock, PhD (1)  ·  Danielle M Kerkovitch, Ph.D. (1)  ·  David A Brown, PhD, PT (1)  ·  David Tanne, MD (1)  ·  David Wolff, Ph.D., Special Assistant to the Director (1)  ·  Edward Taub, Ph.D. (1)  ·  Elliot Roth, MD (1)  ·  Eva Holmgren, PhD student (1)

Results publications

PMID 12052996, PMID 14568122, PMID 14617717, PMID 16424373, PMID 17895349, PMID 17904594, PMID 18720112, PMID 19520987, PMID 19926154, PMID 20435515, PMID 20591171, PMID 21448576, PMID 22627983, PMID 26945226, PMID 28228578, PMID 34695300, PMID 38768068

NIH funding

R01DC007387 (1), R44NS060192 (1)